We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
101
CALL
QuidelOrtho
QDEL
$1.14B
$4.54M 0.2%
+25,300
New +$5.62M
APLT
102
PUT
DELISTED
Applied Therapeutics
APLT
$4.4M 0.19%
+200,000
New +$4.16M
ARCT icon
103
PUT
Arcturus Therapeutics
ARCT
$164M
$4.34M 0.19%
+100,000
New +$6.77M
CHAQ.U
104
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.24M 0.19%
400,000
– –
DMAC icon
105
DiaMedica Therapeutics
DMAC
$342M
$4.21M 0.19%
415,000
– –
CRIS icon
106
CALL
Curis
CRIS
$9.78M
$4.2M 0.19%
+1,281
New +$1.54M
TVRD
107
Tvardi Therapeutics
TVRD
$19.7M
$4.14M 0.18%
7,598
– –
ANAB icon
108
CALL
AnaptysBio
ANAB
$1.58B
$3.92M 0.17%
+182,100
New +$4.42M
KDMN
109
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.89M 0.17%
936,615
– –
FSDC
110
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$3.85M 0.17%
+350,000
New +$3.61M
TCRR
111
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.76M 0.17%
+121,486
New +$3.07M
INMB icon
112
INmune Bio
INMB
$46.5M
$3.75M 0.17%
+217,568
New +$2.05M
CASI
113
DELISTED
CASI Pharmaceuticals
CASI
$3.74M 0.16%
126,815
-27,176
-18% -$591K
GOSS icon
114
CALL
Gossamer Bio
GOSS
$82.9M
$3.69M 0.16%
381,300
+300,000
+369% +$2.96M
FATE icon
115
PUT
Fate Therapeutics
FATE
$286M
$3.53M 0.16%
38,800
-11,300
-23% -$702K
FATE icon
116
CALL
Fate Therapeutics
FATE
$286M
$3.5M 0.15%
38,500
-11,600
-23% -$720K
PASG icon
117
Passage Bio
PASG
$14.4M
$3.5M 0.15%
+6,835
New +$2.74M
ZGNX
118
DELISTED
Zogenix, Inc.
ZGNX
$3.48M 0.15%
174,091
-8,500
-5% -$174K
XENE icon
119
Xenon Pharmaceuticals
XENE
$6.06B
$3.43M 0.15%
223,173
– –
STTK icon
120
Shattuck Labs
STTK
$675M
$3.41M 0.15%
+65,000
New +$2.09M
PHAT icon
121
Phathom Pharmaceuticals
PHAT
$708M
$3.32M 0.15%
+100,000
New +$4.05M
ARNA
122
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.27M 0.14%
42,500
-217,500
-84% -$16.3M
ITCI
123
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.18M 0.14%
100,000
– –
CHMA
124
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.18M 0.14%
730,299
-899,334
-55% -$3.75M
SNDX icon
125
Syndax Pharmaceuticals
SNDX
$1.69B
$3.13M 0.14%
+140,913
New +$2.92M
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.